GenVec
Lua error in package.lua at line 80: module 'strict' not found.
| GenVec | |
| Public company | |
| Traded as | NASDAQ: GNVC |
| Industry | Pharmaceuticals |
| Headquarters | Gaithersburg, Maryland, United States |
|
Key people
|
Douglas J. Swirsky, President and CEO |
| Products | CGF166Clinical trial#Phase 1/2 |
 |
|
|
Number of employees
|
13 |
| Website | www.genvec.com |
GenVec, Inc. (NASDAQ: GNVC) is a biopharmaceutical company working to build a pipeline of therapeutics and vaccines based on its adenovector technology platform that can realize the promise of gene-based medicine. The company's lead product candidate for hearing loss and balance disorders, partnered with Novartis, is in a first-in-man gene delivery Phase 1/2 clinical trial in patients with severe to profound hearing loss. GenVec therapeutics and vaccines have been administered to over 3,000 clinical study subjects.
References
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |
